1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Future needs for continuing innovation in hemophilia : improving outcomes for individuals of all severities, including women and those in resource-constrained regions
(
- Contribution to journal › Scientific review
-
Mark
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8) : a prospective, multicentre, open-label, randomised, phase 3a trial
(
- Contribution to journal › Article
-
Mark
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal
2024) In Haemophilia(
- Contribution to journal › Article
-
Mark
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024) In Haemophilia(
- Contribution to journal › Article
- 2023
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
International consensus recommendations on the management of people with haemophilia B
(
- Contribution to journal › Scientific review
-
Mark
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
(
- Contribution to journal › Article
- 2021
-
Mark
Principles of Care for Acquired Hemophilia
(
- Contribution to journal › Article
-
Mark
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors
(
- Contribution to journal › Scientific review